 |
 |
Phoenix Pharmaceuticals, Inc.
|
 |
LGR7 (Relaxin Receptor 1)
and LGR8 (Relaxin Receptor 2)
Two Newly Identified orphan G Protein-Coupled Receptors for
Insulin-like peptide 3 & 7

A receptor for relaxin.
The different signal transduction pathways involved in the up-regulation
of cAMP by the peptide hormone relaxin (RLX). When relaxin binds
to its G protein-coupled receptor, LGR7 or LGR8, a G protein signaling
pathway is activated leading to stimulation of adenylate cyclase
(AC) and an increase in cAMP. Binding of relaxin to its receptor
also may activate a tyrosine kinase pathway that inhibits the activity
of a phosphodiesterase (PDE) that degrades cAMP . |
| Richard Ivell. Science, Vol 295, Issue 5555, 637-638 , 25 January
2002 |
 |
|
 |
| |
| |
LGR7 |
LGR8 |
| |
Max*
|
IC50
|
Max
|
IC50
|
| INSL3 |
442.4 ± 2.1
|
32.9 ± 9.1
|
ND^
|
1576 ± 592
|
| INSL7/H3 Relaxin |
ND
|
ND
|
336.9 ± 12.3
|
0.19 ± 0.08
|
| |
IC50
values are in nM |
|
*Max, maximal levels of cAMP production
(pmol/2 × 105 cells)
|
| ^ND,
not determined due to nonsaturation |
|
Sudo S, et al. J Biol Chem. 2003 Mar 7;278(10):7855-62.
Epub 2002 Dec 27.
|
|
|
 |
 |
 |
| |
LGR7 |
LGR8 |
|
Max* |
IC50 |
Max |
IC50 |
| INSL3 |
442.4 ± 2.1 |
32.9 ± 9.1 |
ND^ |
1576 ± 592 |
| INSL7/H3 Relaxin |
ND |
ND |
336.9 ± 12.3 |
0.19 ± 0.08 |
| |
IC50 values are in nM |
|
*Max, maximal levels of cAMP production
(pmol/2 × 105 cells) |
| ^ND, not determined due to
nonsaturation |
|
Sudo S, et al. J Biol Chem. 2003 Mar 7;278(10):7855-62.
Epub 2002 Dec 27. |
|
| LGR7 is activated by porcine relaxin and H2 relaxin as well as H3
relaxin, whereas LGR8 is activated by porcine relaxin, H2 relaxin,
and INSL3. A, ligand-stimulated cAMP production mediated by LGR7.
B, ligand-mediated cAMP production mediated by LGR8. Purified porcine
relaxin, recombinant H2 relaxin, synthetic H3 relaxin, and synthetic
INSL3 were used. Sudo S, et al. J Biol Chem. 2003 Mar 7;278(10):7855-62.
Epub 2002 Dec 27. |
|
| |
| Direct binding of 33P-labeled H2 relaxin to LGR7 and LGR8 and competition
by relaxin-related peptides. A, Scatchard plot analyses of 33P-labeled
H2 binding to LGR7 and LGR8. B, competition of 33P-labeled H2 relaxin
binding to LGR7 by relaxin-related peptides. C, competition of 33P-labeled
H2 relaxin binding to LGR8 by relaxin-related peptides. D, the soluble
ectodomain of LGR7 (7BP) blocks H3 relaxin stimulation of cAMP production
by LGR7-expressing cells. Sudo S, et al. J Biol Chem. 2003 Mar 7;278(10):7855-62.
Epub 2002 Dec 27. |
|
| LGR7 (Relaxin Receptor 1) and LGR8
(Relaxin Receptor 2) Antibodies for Immunohistochemistry |
 |
 |
| |
|
| LGR7
(735-757), (Human) Antibody for IHC |
|
Tissue
Sample |
Rat
uterus |
|
Fixative
|
10%
formalin |
|
Embedding
|
paraffin
|
|
Negative
Control |
No
primary antibody |
|
Pretreatment
|
Intact
|
|
Blocking
|
2%
Normal Goat Serum, 3%H2O2 |
|
Primary
Antibody |
LGR7
(735-757), (Human) Antiserum (Catalog
No.: H-001-53) |
|
Optimal
Dilution |
1:100
(1
hour at RT ) |
|
Secondary
Antibody |
Goat
Anti-Rabbit IgG, Biotinylated (1:400) |
|
Amplification
|
ABC
(Vector) |
|
Detection
System |
HRP
|
|
Substrate
|
DAB
(Sigma) |
|
Counterstained
|
Hematoxylin
|
|
|
|
| |
|
| LGR8(737-754),
Cys0, (H) Antibody for IHC |
| Tissue
Sample |
Rat
hypothalamus |
| Fixative
|
10%
formalin |
| Embedding
|
paraffin
|
| Negative
Control |
No
primary antibody |
| Pretreatment
|
Pronase
|
| Blocking
|
2%
Normal Goat Serum, 3%H2O2 |
| Primary
Antibody |
LGR8
(737-754), Cys0, (Human) Antiserum (Catalog
No.: H-001-54) |
| Optimal
Dilution |
1:100
(1
hour at RT ) |
| Secondary
Antibody |
Goat
Anti-Rabbit IgG, Biotinylated (1:400) |
| Amplification
|
ABC
(Vector) |
| Detection
System |
HRP
|
| Substrate
|
DAB
(Sigma) |
| Counterstained
|
Hematoxylin
|
|
|
| Tissue distribution of LGR7, as assessed by immunohistochemical
analysis in rodent tissues. Uterine tissues were obtained from
postpartum rats; vagina and cervix were from rats at 19 days
of pregnancy. Specific staining with antibody to LGR7 (14) in
uterus (a), vagina (c), and cervix (e) is indicated by arrows.
Nonimmune serum showed negligible staining in uterus (b), vagina
(d), and cervix (f). Abbreviations: EM, endometrium; MM, myometrium;
ML, muscularis layer; MU, mucosal layer; EC, endocervix. Immunohistochemical
analysis was performed as described (6). Magnifications, ×100.
Hsu S.Y., et al. Science 2002 Jan 15;295(5555):671-4 |
| |
| |
| |
| |
|
Activation of orphan receptors by the hormone relaxin Relaxin
is a hormone important for the growth and remodeling of reproductive
and other tissues during pregnancy. Although binding sites for relaxin
are widely distributed, the nature of its receptor has been elusive.
Here, we demonstrate that two orphan heterotrimeric guanine nucleotide
binding protein (G protein)-coupled receptors, LGR7 and LGR8, are
capable of mediating the action of relaxin through an adenosine
3',5'-monophosphate (cAMP)-dependent pathway distinct from that
of the structurally related insulin and insulin-like growth factor
family ligand. Treatment of antepartum mice with the soluble ligand-binding
region of LGR7 caused parturition delay. The wide and divergent
distribution of the two relaxin receptors implicates their roles
in reproductive, brain, renal, cardiovascular, and other functions.
Hsu S.Y., et al. Science 2002 Jan 15;295(5555):671-4
|
H3 relaxin is a specific ligand for LGR7
and activates the receptor by interacting with both the ectodomain
and the exoloop 2
Leucine-rich repeat-containing, G protein-coupled receptors (LGRs)
represent a unique subgroup of G protein-coupled receptors with
a large ectodomain. Recent studies demonstrated that relaxin activates
two orphan LGRs, LGR7 and LGR8, whereas INSL3/Leydig insulin-like
peptide specifically activates LGR8. Human relaxin 3 (H3 relaxin)
was recently discovered as a novel ligand for relaxin receptors.
Here, we demonstrate that H3 relaxin activates LGR7 but not LGR8.
Taking advantage of the overlapping specificity of these three ligands
for the two related LGRs, chimeric receptors were generated to elucidate
the mechanism of ligand activation of LGR7. Chimeric receptor LGR7/8
with the ectodomain from LGR7 but the transmembrane region from
LGR8 maintains responsiveness to relaxin but was less responsive
to H3 relaxin based on ligand stimulation of cAMP production. The
decreased ligand signaling was accompanied by decreases in the ability
of H3 relaxin to compete for (33)P-relaxin binding to the chimeric
receptor. However, replacement of the exoloop 2, but not exoloop
1 or 3, of LGR7 to the chimeric LGR7/8 restored ligand binding and
receptor-mediated cAMP production. These results suggested that
activation of LGR7 by H3 relaxin involves specific binding of the
ligand to both the ectodomain and the exoloop 2, thus providing
a model with which to understand the molecular basis of ligand signaling
for this unique subgroup of G protein-coupled receptors.
Sudo S, et al. J Biol Chem. 2003 Mar 7;278(10):7855-62. Epub 2002
Dec 27. |
GREAT/LGR8 is the only receptor for insulin-like 3 peptide During
male development testes descend from their embryonic intraabdominal
position into the scrotum. Two genes, encoding the insulin-like
3 peptide (INSL3) and the GREAT/LGR8 G protein-coupled receptor,
control the differentiation of gubernaculum, the caudal genitoinguinal
ligament critical for testicular descent. It was established that
the INSL3 peptide activates GREAT/LGR8 receptor in vitro. Mutations
of Insl3 or Great cause cryptorchidism (undescended testes) in mice.
Overexpression of the transgenic Insl3 causes male-like gubernaculum
differentiation, ovarian descent into lower abdominal position,
and reduced fertility in females. To address the question whether
Great deletion complements the mutant female phenotype caused by
the Insl3 overexpression, we have produced Insl3 transgenic mice
deficient for Great. Such females had a wild-type phenotype, demonstrating
that Great was the only cognate receptor for Insl3 in vivo. We have
established that pancreatic HIT cells, transfected with the INSL3
cDNA, produce functionally active peptide. Analysis of five INSL3
mutant variants detected in cryptorchid patients showed that P49S
substitution renders functionally compromised peptide. Therefore,
mutations in INSL3 might contribute to the etiology of cryptorchidism.
We have also showed that synthetic insulin-like peptides (INSL4
and INSL6) were unable to activate LGR7 or GREAT/LGR8.
Bogatcheva NV, et al. Mol Endocrinol. 2003 Dec;17(12):2639-46.
Epub 2003 Aug 21. |
| |
| |
References:
- Hsu, S. Y.; Nakabayashi, K.; Nishi, S.; Kumagai, J.; Kudo,
M.; Sherwood, O. D.; Hsueh, A. J. W. : Activation of orphan
receptors by the hormone relaxin. Science 295: 671-674,
2002.
- Hsu, S. Y.; Kudo, M.; Chen, T.; Nakabayashi, K.; Bhalla,
A.; van der Spek, P. J.; van Duin, M.; Hsueh, A. J. W. :
The three subfamilies of leucine-rich repeat-containing
G protein-coupled receptors (LGR): identification of LGR6
and LGR7 and the signaling mechanism for LGR7. Molec. Endocr.
14: 1157-1271, 2000.
- Zhao, L.; Roche, P. J.; Gunnersen, J. M.; Hammond, V.
E.; Tregear, G. W.; Wintour, E. M.; Beck, F. : Mice without
a functional relaxin gene are unable to deliver milk to
their pups. Endocrinology 140: 445-453, 1999.
- Converse P. J. et al. OMIM #606654
|
|
| |
|
|